We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

SCREENING PROGRAM Sample Clauses

SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within [*] following the date of receipt of such Target and complete such screening obligations within [*] following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD). (b) Notwithstanding any provision of this Agreement to the contrary, it is understood and agreed that while NeoGenesis will attempt to complete the Program within thirty six (36) months following the Effective Date, in the event and to the extent that NeoGenesis has not completed the Program with respect to any Target(s) disclosed by OGS within thirty three (33) months following the Program Commencement Date (or thereafter with respect to Targets that are excluded by NeoGenesis as contemplated by Section 2.1(a)) NeoGenesis will continue to perform the Program during the period following the expiration of thirty six (36) months following the Effective Date until NeoGenesis completes the Program for each Target submitted in accordance with Section 2.1(a) and NeoGenesis shall not xxxx OGS any additional fees with respect to the work required to complete the Program with respect to such Targets following the expiration of such thirty six (36) month period; PROVIDED, OGS has paid all fees required under Section 4.2 and PROVIDED FURTHER that NeoGenesis may xxxx OGS for any additional fees due NeoGenesis in respect of "additional" work as contemplated by ATTACHMENT A (Items 6-7).
SCREENING PROGRAM. 13 3.1 Screening Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.1 Screening by Aurora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.2
SCREENING PROGRAM. NeoGenesis will apply use its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. NeoGenesis shall commence the Program following the date the Targets are delivered to NeoGenesis and shall complete the Program within [*] following the date that the Targets are delivered to NeoGenesis, unless the parties agree in writing to extend the period for performance of the Program (the SCREENING PERIOD).
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE B. Extension Assay *** *** FTE C. Neurotoxicity *** *** FTE D. Specificity *** *** FTE PPI will make available *** FTE's to the Screening Program immediately following the Effective Date. These FTE's will either be new hires or redeployments of existing personnel. PPI anticipates that it will be evaluating BI compounds in assays A-D within 6 weeks of first receiving compounds from BI. All Applicable data will be supplied to BI in PC compatible form (e.g. ASCI II or Excel files). All BI compounds will be handled or disposed of in accordance with BI's written instructions. A. Nucleation Assay: A rapid high-throughput primary screen The nucleation assay *** Approximately 13 lines omitted *** B. Extension Assay: *** The extension assay *** Approximately 6 lines omitted *** C. Neurotoxicity Assay: in vitro Cellular Efficacy *** Approximately 10 lines omitted *** D. Amyloid Specificity Assays *** Approximately 9 lines omitted ***
SCREENING PROGRAMThe Program to be performed by NeoGenesis with respect to the Targets will screen compounds contained in the NeoGenesis NeoMorph Screening Library as updated from time to time by NeoGenesis (collectively, such compounds are the Compounds).
SCREENING PROGRAM. (a) NeoGenesis will use its ALIS method to screen the NeoMorph Library for activity with respect to each Screening Target for purposes of identifying potentially useful chemical compounds for further *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. (b) It is understood and agreed that while NeoGenesis will use Commercially Reasonable efforts to complete the Screening Program for all three Screening Targets within [*] following the Effective Date (the SCREENING PERIOD) and complete the Hit Exploration Program for all [*] Screening Targets within [*] following the Effective Date, in the event and to the extent that NeoGenesis has not completed the Screening Program with respect to any Screening Target(s) within such [*] period or completed the Hit Exploration Program within such [*] period, NeoGenesis will continue to perform the applicable Program services during the period following the expiration of the applicable period until NeoGenesis completes the Program for each Screening Target submitted in accordance with Sections 2.1-2.2 at no additional cost.
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE
SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in Attachment A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within thirty (30) days following the date of receipt of such Target and complete such screening obligations within ninety (90) days following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the Screening Period).
SCREENING PROGRAM 

Related to SCREENING PROGRAM

  • Training Program It is agreed that there shall be an Apprenticeship Training Program, the provisions of which are set forth in Exhibit "D", which is attached hereto and forms part of this Agreement.

  • Training Programs All employees shall successfully complete all necessary training prior to being assigned work (e.g., all employees will complete health and safety training prior to being assigned to task). Nothing in this Article or provision shall constitute a waiver of either party’s bargaining obligations or defenses. The Employer still has an obligation to notify and bargain changes in terms and conditions of employment with the exclusive representative.

  • Screening After you sign and date the consent document, you will begin screening. The purpose of the screening is to find out if you meet all of the requirements to take part in the study. Procedures that will be completed during the study (including screening) are described below. If you do not meet the requirements, you will not be able to take part in the study. The study investigator or study staff will explain why. As part of screening, you must complete all of the items listed below: • Give your race, age, gender, and ethnicity • Give your medical history o You must review and confirm the information in your medical history questionnaire • Give your drug, alcohol, and tobacco use history • Give your past and current medication and treatment history. This includes any over-the-counter or prescription drugs, such as vitamins, dietary supplements, or herbal supplements, taken in the past 28 days • Height and weight will be measured • Physical exam will be done • Electrocardiogram (ECG) will be collected. An ECG measures the electrical activity of the heart • You may be tested for COVID-19 o Blood tests for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C o Blood tests to see how your blood clots ▪ Fibrinogen ▪ PT/INR/aPTT o Blood tests for amylase and lipase (enzymes that help with digestion, Part B only) o Blood tests for a lipid (fats) panel (Part B only) ▪ Total cholesterol ▪ Triglycerides ▪ HDL ▪ Direct HDL o Blood tests to check your thyroid function (Part B and Part C only) ▪ TSH ▪ Free T4 o Urine to test for drugs of abuse (illegal and prescription) o Urine tests to check your albumin/ creatinine ratio o Females who have not had a period for at least 12 months in a row will have a blood hormone test to confirm they cannot have children • The study investigator may decide to do an alcohol breath test • The use of proper birth control will be reviewed (males only) • You will be asked “How do you feel?” HIV, hepatitis B, and hepatitis C will be tested at screening. If anyone is exposed to your blood during the study, you will have these tests done again. If you have a positive test, you cannot be in or remain in the study. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). If your HIV test is positive, you will be told about the results. It may take weeks or months after being infected with HIV for the test to be positive. The HIV test is not always right. Having certain infections or positive test results may have to be reported to the State Department of Health. This includes results for HIV, hepatitis, and other infections. If you have any questions about what information is required to be reported, please ask the study investigator or study staff. Although this testing is meant to be private, complete privacy cannot be guaranteed. For example, it is possible for a court of law to get health or study records without your permission.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Research Program The term “

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Pilot Programs The Employer may develop voluntary pilot programs to test the acceptability of various risk management programs. Incentives for participation in such programs may include limited short-term improvements to the benefits outlined in this Article. Implementation of such pilot programs is subject to the review and approval of the Joint Labor-Management Committee on Health Plans.

  • Evaluation, Testing, and Monitoring 1. The System Agency may review, test, evaluate and monitor Grantee’s Products and services, as well as associated documentation and technical support for compliance with the Accessibility Standards. Review, testing, evaluation and monitoring may be conducted before and after the award of a contract. Testing and monitoring may include user acceptance testing. Neither the review, testing (including acceptance testing), evaluation or monitoring of any Product or service, nor the absence of review, testing, evaluation or monitoring, will result in a waiver of the State’s right to contest the Grantee’s assertion of compliance with the Accessibility Standards. 2. Grantee agrees to cooperate fully and provide the System Agency and its representatives timely access to Products, records, and other items and information needed to conduct such review, evaluation, testing, and monitoring.